Concepedia

Publication | Closed Access

Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.

79

Citations

0

References

1996

Year

John M. de Klerk, Alfred D. van het Schip, Bernard A. Zonnenberg, Anouk van Dijk, J M Quirijnen, G.H. Blijham, Peter P. van Rijk
PubMed

Abstract

The maximum tolerated administered activity of 186Re-HEDP in patients with metastatic breast cancer is 2405 MBq (65 mCi). Thrombocytopenia proved to be the dose-limiting toxicity, which could not be predicted adequately by the administered activity. Changes of alkaline phosphatase levels suggest anti-tumor effects of 186Re-HEDP.